08:19 AM EDT, 10/09/2025 (MT Newswires) -- Ligand Pharmaceuticals ( LGND ) said Thursday its partner SQ Innovation received US Food and Drug Administration approval for Lasix Onyu, an at-home furosemide treatment for edema in adults with chronic heart failure that can be injected under the skin.

The drug-device uses a high-concentration furosemide delivered via a small Infusor with a unit that can be used for up to 48 treatments, and a single-use sterile syringe for injecting, the company said.

Under a 2019 Captisol license and supply deal with SQ Innovation, Ligand is eligible for milestones, a low-single-digit royalty, and material sales tied to Lasix Onyu, the company added.

In addition, the company said it expects US availability in Q4.

Shares of the company were up more than 1% in recent Thursday premarket activity.